• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Intuitive Surgical reveals details of FDA warning letter, follow-up visit

Intuitive Surgical reveals details of FDA warning letter, follow-up visit

July 23, 2013 By Arezu Sarvestani

Intuitive Surgical logo

Robot surgical devices maker Intuitive Surgical (NSDQ:ISRG) has had a rough few months, and the tension wasn’t much eased by news that the company had been the subject of an FDA warning letter following a facilities inspection.

In its most recent financial report, Intuitive said that the FDA had issued a Form FDA 483 warning citing 4 "objectionable observations" from the inspection.

"These 4 observations relate to the reporting of field actions, information which is to be included on reports of field actions, lack of a written procedure for changes to certain product claims, and design input documentation," according to a company financial report. "In addition, the FDA collected in electronic form, samples of all advertising and promotional material for review."

The agency is planning a come-back visit to take a closer look at the company’s recall procedures, senior finance director Calvin Darling said in a recent earnings call.

Intuitive responded to each of the observations both during the inspection and afterwards, according to the company. The FDA nonetheless issued a warning letter dated July 16 and informed the company that inspectors will come back for a follow-up tour of the facilities.

"We believe that the FDA’s observations are addressable and we are in the process of correcting them," Intuitive Surgical reported.

The inspection and news of the warning letter dragged ISRG shares down when they were 1st reported in June. The plunge was the latest in a slew of Wall Street slides that have cut 31%, amounting to more than $177 per share, from ISRG prices the start of February.

In recent months the company, once a Wall Street darling, has faced an FDA probe into surgical complication rates, an American Congress of Obstetricians & Gynecologists statement questioning the benefits of da Vinci surgery, a high-profile patient injury lawsuit painting the company as an aggressor, a surgical instrument crack warning and a shareholder class action lawsuit against the company and its leadership.

Earlier this month the device maker released its Q2 earnings report, posting lackluster figures and slashing its expectations for the rest of the year.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Surgical Robotics Tagged With: Intuitive Surgical, Warning Letter

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy